Praxis Precision Medicines (PRAX) is trading higher as investors react to new sell-side support: Raymond James initiated coverage with a Strong Buy rating and a published price target of $815. The initiation adds another high-profile bullish view to a name that has already drawn increased attention tied to upcoming U.S. regulatory catalysts in essential tremor and rare epilepsy-related indications. �citeturn2search5

In biotech, fresh initiations can move stocks when they arrive close to major clinical or FDA decision points because they can expand the buyer base and reset valuation frameworks. The Raymond James call lands as the market continues to price PRAX around FDA-driven outcomes for its lead programs, with investors increasingly focused on timelines, labeling risk, and launch economics rather than early-stage science alone. �citeturn2search5

Recent company communications and market summaries point to an active FDA calendar in 2026, including review timelines tied to its lead assets and a PDUFA target date that investors are treating as a major binary event. Traders typically re-rate CNS-focused biotech names into these decision windows, particularly when multiple Wall Street firms highlight the same upcoming milestones. �citeturn2search6

Investors will monitor follow-on analyst reactions, any additional target changes, and signs of elevated options activity that can accompany catalyst-driven momentum. The next major swing factor is whether incoming FDA updates and any related commercial-readiness disclosures reinforce the bullish thesis implied by the new $815 target. �citeturn2search1